- Home
- ICCM vs PYXS Comparison
ICCM vs PYXS Comparison
Compare ICCM & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- PYXS
- Stock Information
- Founded
- ICCM 2006
- PYXS 2018
- Country
- ICCM Israel
- PYXS United States
- Employees
- ICCM N/A
- PYXS N/A
- Industry
- ICCM
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- PYXS Health Care
- Exchange
- ICCM Nasdaq
- PYXS Nasdaq
- Market Cap
- ICCM 70.1M
- PYXS 64.4M
- IPO Year
- ICCM N/A
- PYXS 2021
- Fundamental
- Price
- ICCM $1.03
- PYXS $1.09
- Analyst Decision
- ICCM Strong Buy
- PYXS Strong Buy
- Analyst Count
- ICCM 1
- PYXS 6
- Target Price
- ICCM $2.50
- PYXS $9.20
- AVG Volume (30 Days)
- ICCM 196.6K
- PYXS 520.0K
- Earning Date
- ICCM 05-27-2025
- PYXS 05-20-2025
- Dividend Yield
- ICCM N/A
- PYXS N/A
- EPS Growth
- ICCM N/A
- PYXS N/A
- EPS
- ICCM N/A
- PYXS N/A
- Revenue
- ICCM $3,291,000.00
- PYXS $16,146,000.00
- Revenue This Year
- ICCM $97.02
- PYXS N/A
- Revenue Next Year
- ICCM $212.86
- PYXS N/A
- P/E Ratio
- ICCM N/A
- PYXS N/A
- Revenue Growth
- ICCM 1.92
- PYXS N/A
- 52 Week Low
- ICCM $0.48
- PYXS $0.83
- 52 Week High
- ICCM $1.66
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- ICCM 37.29
- PYXS 51.47
- Support Level
- ICCM $1.00
- PYXS $1.05
- Resistance Level
- ICCM $1.34
- PYXS $1.33
- Average True Range (ATR)
- ICCM 0.08
- PYXS 0.11
- MACD
- ICCM -0.01
- PYXS 0.01
- Stochastic Oscillator
- ICCM 8.82
- PYXS 41.46
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.